BioSpace News Archive

The Phase 2/3 RELATIVITY-047 trial served as the basis for this application, in which a statistically significant and clinically meaningful benefit was observed with relatlimab and nivolumab over Opdivo monotherapy

G1 Therapeutics, Inc., a commercial-stage oncology company, announced that the permanent J-code for COSELA™ that was issued in July 2021 by the Centers for Medicare & Medicaid Services is now effective for provider billing for all sites of care.

Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced two poster presentations at the SITC 2021 Annual Meeting,

I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in October.

Virpax ® Pharmaceuticals, Inc. today announced that Chairman and CEO Anthony P. Mack will present an overview of Virpax and take part in a fireside chat moderated by Noble Capital Markets senior equity research analyst, Gregory Aurand at the Pain Management Virtual Investor Forum on Thursday, October 7, 2021 at 9:00 a.m. Eastern time.

Mosaic ImmunoEngineering Inc. today announced that Nicole F. Steinmetz, Ph.D., acting chief scientific officer and co-founder of Mosaic and the director of the UC San Diego Center for Nano-ImmunoEngineering , will will deliver an oral presentation at the World Molecular Imaging Congress 2021 (WMIC) to be held virtually on October 6-9, 2021.

BioNTech SE today announced that new clinical and preclinical data will be presented in six posters and one presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), being held both in person and virtually from November 10 - 14, 2021.

Ikena Oncology, Inc. today announced that three abstracts highlighting the company’s Aryl Hydrocarbon Receptor (AHR) antagonist program, with novel inhibitor IK-175, will be presented at the SITC 2021 Annual Meeting.

Breckenridge Pharmaceutical, Inc. announces today that it has launched the 10mg strength of Everolimus Tablets (generic for Afinitor®).

Creative Medical Technology Holdings Inc. (OTC – CELZ) announced today filing a new patent application covering nanoparticles called “exosomes” secreted by cells of its MyeloCelz™ platform and their use in the treatment of type 1 diabetes.